Physiology and Pathophysiology of Complement: Progress and Trends

References

• Nuttal G. Experimente uber die bakterienfeidlichen einflusse des thierischen korpers. Z Hyg Infektionskr 1888; 4: 353–95
   Google Scholar
• Buchner H. Ueber die nahere Natur der bekterientodtenden substanz im blutserum. Central Bakteriol Parasitol 1889; 6: 561–5
   Google Scholar
• Ehrlich P., Morgenroth J. Zur theorie der lysenwirkung. Berlin Klin Wschr 1899; 36: 6–9
   Google Scholar
• Mayer M. M. Highlights of complement research during the past twenty-five years. Immu-nochemistry 1970; 7: 485–96
   Google Scholar
• Mayer M. M. Complement: historical perspectives and some current issues. Complement 1984; 1: 2–26
   Google Scholar
• Bumet F. M. Complement. Cellular immunology. Cambridge University Press, Cambridge 1969; 160–2
   Google Scholar
• Gigli I., Austen K. F. Phylogeny and function of the complement system. Annu Rev Microbiol 1971; 25: 309–32
   Google Scholar
• Dodds A. W., Day A. J. The phylogeny and evolution of the complement system. Complement in health and disease, K. Whaley, M Loos, J. M. Weiler. Kluwer, London 1993; 39–88
   Google Scholar
• Nonaka M., Fujii T., Kaidoh T., et al. Purification of a lamprey component protein homologous to the third component of the mammalian complement system. J Immunol 1984; 133: 3242–9
   PubMed Web of Science ®Google Scholar
• Hughes-Jones N. C. The classical pathway. Immunobiology of the complement system, G. D. Ross. Academic Press, Orlando 1986; 21–44
   Google Scholar
• Loos M. Classical pathway of activation. The complement system, K. Rother, G. O. Till. Springer-Verlag, Berlin 1985; 136–154
   Google Scholar
• Ziccardi R. J., Cooper N. R. The subunit composition and sedimentation properties of human C1. J Immunol 1977; 118: 2047–52
   Google Scholar
• Villiers C. L., Arlaud G. J., Colomb M. G. Domain structure and associated functions of subcomponents Clr and Cls of the first component of human complement. Proc Natl Acad Sci USA 1985; 82: 4477–81
   Google Scholar
• Colomb M. G., Arlaud G. J. Villiers C. L. Activation. afCl.Philos Trans R SocLondon 1984; 306: 283–92
   Google Scholar
• Schreiber R. D., Muller-Eberhard H. J. Fourth component of human complement: description of a three polypeptide chain structure. J Exp Med 1974; 140: 1324–35
   PubMed Web of Science ®Google Scholar
• Campbell R. D., Gagnon J., Porter R. R. Amino acid sequence around the thiol and reactive acyl groups of human complement component C4. Biochem J 1981; 199: 359–70
   PubMed Web of Science ®Google Scholar
• Harrison R. A., Thomas ML, Tack B. F. Sequence determination of the thiol ester site of the fourth component of human complement. Proc Natl Acad Sci USA 1981; 78: 7388–92
   Google Scholar
• De Bruijn MHL, Fey G. H. Human complement component C3: cDNA coding sequence and derived primary structure. Proc Natl Acad Sci USA 1985; 82: 708–12
   PubMed Web of Science ®Google Scholar
• Ooi Y. M., Colten H. R. Biosynthesis and post-synthetic modification of a precursor (pro-C5) of the fifth component of mouse complement (C5). J Immunol 1979; 123: 2494–8
   Google Scholar
• Tack B. F., Harrison R. A., Janatova J., et al. Evidence for presence of an internal thiolester bond in third component of human complement. Proc Natl Acad Sci USA 1980; 77: 5764–8
   PubMed Web of Science ®Google Scholar
• Pillemer L., Blum L., Lepow I. H., et al. The properdin system and immunity. I. Demonstration of a new serum protein and its role in immune phenomena. Science 1954; 120: 279–85
   PubMed Web of Science ®Google Scholar
• Nelson R. A. An alternative explanation for the properdin system. J Exp Med 1958; 108: 515–35
   Google Scholar
• Gotze O., Muller-Eberhard H. J. The C3-activator system: an alternative pathway of complement activation. J Exp Med 1971; 134: 90s–108s
   PubMed Web of Science ®Google Scholar
• Gotze O., Muller-Eberhard H. J. The role of properdin in the alternate pathway of complement activation. J Exp Med 1974; 139: 44–57
   Google Scholar
• Pangburn M. K. The alternative pathway. Immunobiology of the complement system, G. D. Ross. Academic Press, Orlando 1986; 45–62
   Google Scholar
• Gotze O. The alternative pathway of activation. 77ie complement system, K. Rother, G. O. Till. Springer-Verlag, Berlin 1985; 154–168
   Google Scholar
• LeSavre P. H., Muller-Eberhard H. J. Mechanism of action of factor D of the alternative complement pathway. J Exp Med 1978; 148: 1498–1509
   PubMed Web of Science ®Google Scholar
• Lachmann P. J., Hughes-Jones N. C. Initiation of complement activation. Springer Semin Immunopathol 1984; 7: 143–62
   PubMed Web of Science ®Google Scholar
• Pangburn M. K., Muller-Eberhard H. J. Relationship of a putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med 1980; 152: 1102–14
   PubMed Web of Science ®Google Scholar
• Fearon D. T., Austen K. F. Activation of the alternative complement pathway due to resistance of zymosan bound amplification convertase to endogenous regulatory mechanisms. Proc Natl Acad Sci USA 1977; 74: 1683–7
   PubMed Web of Science ®Google Scholar
• Fearon D. T., Austen K. F. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J Exp Med 1977; 146: 22–33
   Google Scholar
• Mayer M. M., Imagawa D. K., Ramm L. E., et al. Membrane attack by complement and its consequences. Prog Immunol 1983; 5: 427–44
   Google Scholar
• Esser A. F. The membrane attack pathway of complement. Year Immunol. 1990; 6: 229–44
   Google Scholar
• Hansch G. M. The complement attack phase. The complement system, K. Rother, G. O. Till. Springer-Verlag, Berlin 1985; 202–30
   Google Scholar
• Stolfi R. L. Immune lytic transformation: a state of irreversible damage generated as a result of reaction of the eighth component in the guinea pig complement system. J Immunol 1968; 100: 46–54
   Google Scholar
• Morgan B. P., Imagawa D. K., Dankert J. R., et al. Complement lysis of U937, a nucleated mammalian cell line, in the absence of C9: effect of C9 on C5b-8 mediated cell lysis. J Immunol 1986; 136: 3402–6
   Google Scholar
• DiScipio R., Hughli T. E. The molecular architecture of human complement component C6. J Biol Chem 1989; 264: 16197–206
   Google Scholar
• Mayer M. M. Transmembrane channels produced by complement proteins. Ann NY Acad Sci 1980; 358: 43–63
   Google Scholar
• Sims P. J. Complement pores in erythrocyte membranes: analysis of C8/C9 binding required for functional membrane damage. Biochim Biophys Acta 1983; 732: 541–52
   Google Scholar
• Humphrey J. H., Dourmashkin RR. The lesions in the cell membrane caused by complement. Adv Immunol 1969; 11: 75–115
   PubMedGoogle Scholar
• Tranum-Jensen J., Bhakdi S., Bhakdi-Lehnen B., et al. Complement lysis: the ultrastructure and orientation of the C5b-9 complex on target sheep erythrocyte membranes. Scand J Immunol 1978; 7: 45–56
   Google Scholar
• Podack E. R., Tschopp J. Polymerisation of the ninth component of complement (C9): formation of poly (C9) with a tubular ultrastructure resembling the membrane attack complex of complement. Proc Natl Acad Sci USA 1982; 79: 574–8
   Google Scholar
• Tschopp J., Muller-Eberhard HJ, Podack E. R. Formation of transmembrane tubules by spontaneous polymerisation of the hydrophilic complement component protein C9. Nature 1982; 298: 534–8
   PubMed Web of Science ®Google Scholar
• Dankert J. R., Esser A. F. Proteolytic modification of human complement protein C9: loss of poly(C9) and circular lesion formation without impairment of function. Proc Natl Acad Sci USA 1985; 82: 2128–32
   Google Scholar
• Ramm L. E., Whitlow MB, Mayer M. M. The relationship between channel size and the number of C9 molecules in the C5b-9 complex. J Immunol 1985; 134: 1143–50
   Google Scholar
• DiScipio R. G. The relationship between polymerization of complement component C9 and membrane channel formation. J Immunol 1991; 147: 4239–147
   Google Scholar
• Esser A. F. Big MAC attack: complement proteins cause leaky patches. Immunol Today 1991; 12: 316–8
   PubMedGoogle Scholar
• Bhakdi S., Tranum-Jensen J. Complement lysis: a hole is a hole. Immunol Today 1991; 12: 318–20
   PubMedGoogle Scholar
• Taylor P. W. Non-immunoglobulin activators of the complement system. Activators and inhibitors of complement, R. B. Sim. Amsterdam, KJuwer 1993; 37–68
   Google Scholar
• Reid KBM. Structure-function relationships in the collectins. Biochem Soc Trans 1993; 21: 464–8
   Google Scholar
• Lu J. H., Thiel S., Wiedemann H., et al. Binding of the pentamer/hexamer forms of mannan binding protein to zymosan activates the proenzyme Clr2Cls2 complex of the classical pathway of complement without involvement of Clq. J Immunol 1990; 144: 2287–94
   Google Scholar
• Sato T., Endo Y., Matsuhita M., et al. Molecular characterization of a novel serine protease involved in activation of the complement system by mannose-binding protein. Int Immunol 1994; 6: 665–9
   PubMed Web of Science ®Google Scholar
• Holmskov U., Malhotra R., Sim R. B., et al. Collectins, collagenous C-type lectins of the innate immune system. Immunol Today 1994; 15: 67–74
   PubMedGoogle Scholar
• Schultz D. R., Arnold P. I. Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha-1 -acid glycoprotein and fibrinogen. Semin Arthritis Rheum 1990; 20: 129–47
   PubMed Web of Science ®Google Scholar
• Jiang H. X., Siegel J. N., Gewurz H. Binding and complement activation by C-reactive protein via the collagen-like region of Clq and inhibition of these reactions by monoclonal antibodies to C-reactive protein and Clq. J Immunol 1991; 146: 2324–30
   PubMed Web of Science ®Google Scholar
• Hicks P. S., Saunero-Nava L., DuClos T. W., et al. Serum amyloid P component binds to histones and activates the classical complement pathway. J Immunol 1992; 149: 3689–94
   Google Scholar
• Rogers J., Cooper N. R., Webster S., et al. Complement activation by β-amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1992; 89: 10016–20
   PubMed Web of Science ®Google Scholar
• Pinckard R. N., Olson M. S., Giclas P. C., et al. Consumption of classical complement pathway components by heart subcellular membranes. in vitro and in patients after acute myocardial infarction. J Clin Invest 1975; 56: 740–50
   PubMed Web of Science ®Google Scholar
• Colten H. R., Strunk R. C. Synthesis of complement components in liver and at extrahepatic sites. Complement in health and disease, K. Whaley, M. Loos, J. M. Weiler. Kluwer, Dordrecht 1993; 127–582
   Google Scholar
• McPhaden A. R., Whaley K. Complement biosynthesis by mononuclear phagocytes. Immunol Res 1993; 12: 213–32
   PubMed Web of Science ®Google Scholar
• Hamilton A. O., Jones L., Morrison L., et al. Modulation of monocyte complement synthesis by interferons. Biochem J 1987; 242: 809–15
   Google Scholar
• Strunk R. C., Eidlen DM, Mason R. J. Pulmonary alveolar Type II epithelial cells synthesize and secrete proteins of the classical and alternative complement pathways. J Clin Invest 1988; 81: 1419–26
   PubMed Web of Science ®Google Scholar
• Gue D., Gulati P., Lemereler C., et al. Expression of the components and regulatory proteins of the alternative complement pathway and the membrane attack complex in normal and diseased synovium. Rheumatol Int 1993; 13: 139–46
   Google Scholar
• Gasque P., Julen N., Ischenko A. M., et al. Expression of complement components of the alternative pathway by glioma cell lines. J Immunol 1992; 149: 1381–7
   PubMed Web of Science ®Google Scholar
• Gasque P., Ischenko A. M., Legoedoc C., et al. Expression of the complement classical pathway by human glioma in culture. J Biol Chem 1993; 268: 25068–74
   Google Scholar
• Gasque P., Fontaine M, Morgan B. P. Complement expression in human brain: analysis of the biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J Immunol 1995; 154: 4726–33
   PubMed Web of Science ®Google Scholar
• Davis AE, III, Whitehead A. S., Harrison R. A., et al. Human inhibitor of the first component of complement, CI: characterization of cDNA clones and localization of the gene to chromosome 11. Proc Natl Acad Sci USA 1986; 83: 3161–5
   PubMed Web of Science ®Google Scholar
• Davis AE, III. CI inhibitor and hereditary angioneurotic edema. Annu Rev Immunol 1988; 6: 595–628
   PubMed Web of Science ®Google Scholar
• Fujita T., Gigli I., Nussenzweig V. Human C4-binding protein. II. Role in proteolysis of C4b by C3b-inactivator. J Exp Med 1978; 148: 1044–51
   PubMed Web of Science ®Google Scholar
• Whaley K., Ruddy S. Modulation of the alternative complement pathway by plH globulin. J Exp Med 1977; 144: 1147–55
   Google Scholar
• Smith C. A., Pangbum M. K., Vogel C. W., et al. Molecular architecture of human properdin, a positive regulator of the alternative pathway of complement. J Biol Chem 1984; 259: 4582–8
   PubMed Web of Science ®Google Scholar
• Nicholson-Weller A. Decay accelerating factor (CD55). Membrane defenses against attack by complement and perforins, C. M. Parker. Springer, Berlin 1992; 7–30
   Google Scholar
• Liszewski M. K., Post TW, Atkinson J. P. Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu Rev Immunol 1991; 9: 431–6
   PubMed Web of Science ®Google Scholar
• Wong W. W. Structural and functional correlation of the human complement receptor type 1. J Invest Dermatol 1990; 94: 64S–67S
   PubMed Web of Science ®Google Scholar
• Ross G. D. Complement receptor type 1. Membrane defenses against attack by complement and perforins, C. M. Parker. Springer., Berlin 1992; 31–44
   Google Scholar
• Dahlback B., Podack E. R. Characterization of human S protein, an inhibitor of the membrane attack complex of complement. Biochemistry 1985; 25: 6740–7
   Google Scholar
• Ruoslahti E., Suzuki S., Hayman E. G., et al. Purification and characterization of vitronectin. Methods Enzymol 1987; 144: 430–7
   PubMed Web of Science ®Google Scholar
• Jenne D., Tschopp J. Clusterin: the intriguing guises of a widely expressed glycoprotein. Trends Biochem Sci 1992; 17: 154–9
   PubMed Web of Science ®Google Scholar
• Nemerow G. R., Yamamoto K, Lint T. E. Restriction of C-mediated membrane damage by the eighth component of complement: a dual role for C8 in the complement attachment sequence. J Immunol 1979; 123: 1245–51
   Google Scholar
• Podack E. R. The SC5b-9 complex: formation, isolation, properties and subunit composition. J Immunol 1977; 119: 2024–9
   PubMed Web of Science ®Google Scholar
• Bhakdi S., Fassbender W., Hugo F., et al. Relative inefficiency of terminal complement activation. J Immunol 1988; 141: 3117–22
   PubMed Web of Science ®Google Scholar
• Sugita Y., Nakano Y., Tomita M. Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. J Biochem (Tokyo) 1988; 104: 633–7
   PubMed Web of Science ®Google Scholar
• Davies A., Simmons D. L., Hale G., et al. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the membrane attack complex on homologous cells. J Exp Med 1989; 170: 637–54
   PubMed Web of Science ®Google Scholar
• Meri S., Morgan B. P., Davies A., et al. Human protectin (CD59) an 18,000–20,000 MW complement lysis restricting factor, inhibits C5b-8-catalysed insertion of C9 into bilayers. Immunology 1990; 71: 1–9
   PubMed Web of Science ®Google Scholar
• Walsh L. A., Tone M., Thiuri S., et al. The CD59 antigen: a multifunctional molecule. Tissue Antigens 1992; 40: 213–20
   Google Scholar
• Davies A., Lachmann P. J. Membrane defence against complement lysis: the structure and biological properties of CD59. Immunol Res 1993; 12: 258–75
   PubMed Web of Science ®Google Scholar
• Chenoweth D. E. Complement mediators of inflammation. Immunobiology of the complement system, G. D. Ross. Academic Press, Orlando 1986; 63–86
   Google Scholar
• Kohl J., Bitter-Suermann D. Complement in health and disease.Anaphylatoxins, K. Whaley, M Loos, J Weiler. Kluwer, Lancaster 1993; 299–324
   Google Scholar
• Hugli T. E. Biochemistry and biology of anaphylatoxins. Complement 1986; 3: 111–27
   PubMedGoogle Scholar
• Fernandez H. N., Henson P. M., Otani A., et al. Chemotactic response to human C3a and C5a anaphylatoxins. J Immunol 1978; 120: 102–8
   PubMed Web of Science ®Google Scholar
• Burgi B., BrunnerT Dahinden C. A. The degradation product of the C5a anaphylatoxin C5adcsarg retains basophil-activating properties. Eur J Immunol 1994; 24: 1583–9
   Google Scholar
• Norgauer J., Dobos G., Kownatzki E., et al. Complement fragment C3a stimulates Ca2+ influx in neutrophils via a pertussis toxin sensitive G protein. Eur J Biochem 1993; 217: 289–94
   PubMedGoogle Scholar
• Van Epps D. E., Simpson SJ, Johnson R. Relationship of C5a receptor modulation to the functional responsiveness of human polymorphonuclear leukocytes to C5a. J Immunol 1993; 150: 246–52
   Google Scholar
• Bajaj M. S., Kew R. R., Webster R. O., et al. Priming of human neutrophil functions by tumor necrosis factor. Inflammation 1992; 16: 241–50
   Google Scholar
• Shingu M., Nonaka S., Nishimukai H., et al. Activation of complement in normal serum by hydrogen peroxide and hydrogen peroxide related radicals produced by activated neutrophils. Clin Exp Immunol 1992; 90: 72–8
   PubMed Web of Science ®Google Scholar
• Frank M. M., Fries L. F. The role of complement in inflammation and phagocytosis. Immunol Today 1991; 12: 322–6
   PubMedGoogle Scholar
• Miller G. W., Nussenzweig V. A new complement function: solubilization of antigen-antibody aggregates. Proc Natl Acad Sci USA 1975; 72: 418–22
   PubMed Web of Science ®Google Scholar
• Whaley K., Ahmed AEE. Control of immune complexes by the classical pathway. Behring Inst Mitt 1989; 84: 111–20
   Google Scholar
• Schifferli J. A., Ng Y. C., Pacaud J. P., et al. The role of hypocomplementaemia and low erythrocyte complement receptor type 1 numbers in determining abnormal immune complex clearance in humans. Clin Exp Immunol 1989; 75: 329–35
   PubMed Web of Science ®Google Scholar
• Ng Y. C., Schifferli J. A. Complement, immune complexes and immune complex disease. Complement in health and disease, K. Whaley, M Loos, J Weiler. Kluwer, Lancaster 1993; 199–212
   Google Scholar
• Morgan B. P. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem J 1989; 164: 1–14
   Google Scholar
• Morgan B. P. Effects of the membrane attack complex on nucleated cells. Membrane defenses against attack by complement and perforins, C. M. Parker. Springer, Berlin 1992; 115–40
   Google Scholar
• Figueroa J. E., Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991; 4: 359–95
   PubMed Web of Science ®Google Scholar
• Perlmutter D. H., Colten H. R. Molecular basis of complement deficiencies. Immunodeficiency Rev 1989; 1: 105–33
   PubMedGoogle Scholar
• Morgan B. P., Walport M. J. Complement deficiency and disease. Immunol Today 1990; 12: 301–6
   Google Scholar
• Densen P. Human complement deficiency states and infection. Complement in health and disease, K. Whaley, M Loos, J Weiler. Kluwer, Lancaster 1993; 173–98
   Google Scholar
• Colten H. R., Rosen F. S. Complement deficiencies. Adv Immunol 1992; 10: 785–808
   Google Scholar
• Ross S. C., Densen P. Complement deficiency states and infection. Medicine (Baltimore) 1984; 63: 243–73
   PubMed Web of Science ®Google Scholar
• Meyer O., Hauptmann G., Tappeiner G., et al. Genetic deficiency of C4, C2 or Clq and lupus syndromes. Association with anti-Ro (SS-A) antibodies. Clin Exp Immunol 1985; 62: 678–84
   PubMed Web of Science ®Google Scholar
• Hauptmann G., Goetze J., Uring-Lambert B., et al. Component deficiencies. II. The fourth component. Prog Allergy 1986; 39: 232–49
   Google Scholar
• Glass D., Raum D., Gibson D., et al. Inherited deficiency of the second component of complement: rheumatic disease association. J Clin Invest 1976; 58: 853–9
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P., Laviolette M., Hebert J., et al. C3b inactivator deficiency with immune complex manifestations. Clin Exp Immunol 1982; 47: 197–202
   PubMed Web of Science ®Google Scholar
• Levy M., Halbwachs-Mecarelli L., Gubler M. C., et al. H deficiency in two brothers with atypical dense membranous deposit disease. Kidney Int 1986; 30: 949–56
   PubMed Web of Science ®Google Scholar
• Turner M. W. Deficiency of mannan binding protein – a new complement deficiency syndrome. Clin Exp Immunol 1991; 86(SuppI 1)53–6
   Google Scholar
• Hiemstra P. S., Langeler E., Compier B., et al. Complete and partial deficiencies of complement factor D in a Dutch family. J Clin Invest 1989; 84: 1957–61
   Google Scholar
• Densen P., Weiler J. M., Griffiss J. M., et al. Familial properdin deficiency and fatal meningococcaemia: correction of the bactericidal defect by vaccination. N Engl J Med 1987; 316: 922–6
   PubMedGoogle Scholar
• Sjoholm A. G., Kuijper E. J., Tijssen C. C., et al. Dysfunctional properdin in a Dutch family with meningococcal disease. N Engl J Med 1988; 319: 33–7
   PubMed Web of Science ®Google Scholar
• Wurzner R., Orren A, Lachmann P. J. Inherited deficiencies of the terminal components of human complement. Immunodeficiency Rev 1992; 3: 123–47
   PubMedGoogle Scholar
• Fukomori Y., Yoshimura K., Ohnoki S., et al. A high incidence of C9 deficiency among healthy blood donors in Osaka, Japan. Int Immunol 1989; 1: 85–9
   Google Scholar
• Nagata M., Hara T., Aoki T., et al. Inherited deficiency of ninth component of complement: an increased risk of meningococcal meningitis. J Paediatr 1989; 114: 260–4
   PubMed Web of Science ®Google Scholar
• Davis A. E. Hereditary and acquired deficiencies of CI inhibitor. Immunodeficiency Rev 1989; 1: 207–26
   PubMedGoogle Scholar
• Frank M. M. Hereditary angio-oedema. Complement in health and disease, K. Whaley, M Loos, J. M. Weiler. Lancaster, Kluwer 1993; 229–44
   Google Scholar
• Dacie J. V., Lewis S. M. Paroxysmal nocturnal haemoglobinuria: clinical manifestations, haematology and nature of disease. Semin Haematol 1972; 5: 3–23
   Google Scholar
• Rosse W. Phosphatidylinositol-linked proteins and paroxysmal nocturnal hemoglobinuria. Blood 1990; 75: 1595–1601
   PubMed Web of Science ®Google Scholar
• Hillmen P., Bessler M., Mason P. J., et al. Specific defect in N-acetylglucosamine incorporation in the biosynthesis of the glycosylphosphatidylinositol anchor in cloned cell lines from patients with paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci USA 1993; 90: 5272–6
   PubMed Web of Science ®Google Scholar
• Takahashi M., Takeda J., Hirose S., et al. Deficient biosynthesis of. N-acetylglucosaminyl-phosphatidylinositol, the first intermediate of glycosyl phosphatidylinositol anchor biosynthesis, in cell lines established from patients with paroxysmal nocturnal hemoglobinuria. J Exp Med. 1993; 177: 517–21
   PubMed Web of Science ®Google Scholar
• Mayer M. M. Complement and complement fixation. Experimental immunochemistry, E. A. Kabat, M. M. Mayer. IL: Charles C Thomas, Springfield 1961; 133–65
   Google Scholar
• Whaley K. Measurement of complement activation in clinical practice. Complement Inflammation 1989; 6: 96–102
   Google Scholar
• Cooper N. R., Nemerow GR, Mayes J. T. Methods to detect and quantitate complement activation. Springer Semin Immunopathol 1983; 6: 195–212
   PubMed Web of Science ®Google Scholar
• Porcel J. M., Peakman M., Senaldi G., et al. Methods for assessing complement activation in the clinical immunology laboratory. J Immunol Methods 1993; 157: 1–9
   Google Scholar
• Mollnes T. E. Antigenic changes of complement components: relevance for the analysis of complement activation. Complement Inflammation 1989; 6: 134–41
   Google Scholar
• Maillet F., Fremeaux-Bacchi V., Uhring-Lambert B., et al. Assessment of complement activation in clinical samples. J Immunol Methods 1992; 156: 171–8
   Google Scholar
• Wagner J. L., Hugh T. E. Radioimmunoassay for anaphylatoxins: a sensitive method for determining complement activation products in biological fluids. Anal Biochem 1984; 136: 75–80
   PubMed Web of Science ®Google Scholar
• Hugo F., Kramer S, Bhakdi S. Sensitive ELISA for quantitating the terminal membrane C5b-9 and fluid-phase SC5b-9 complex of human complement. J Immunol Methods 1987; 99: 243–9
   Google Scholar
• Mollnes T. E., Lea T., Froland S. S., et al. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 1985; 22: 197–202
   PubMed Web of Science ®Google Scholar
• Whaley K. Methods in complement for clinical immunologists. Churchill-Livingstone, Edinburgh 1985; 101–15
   Google Scholar
• Morgan B. P. Complement: clinical aspects and relevance to disease. Academic Press, London 1990; 193–210
   Google Scholar
• Rauterberg E. W. Demonstration of complement deposits in tissue. The complement system, K. Rother, G. O. Till. Springer, Berlin 1988; 287–326
   Google Scholar
• Gatenby P. A. The role of complement in the aetiopathogenesis of systemic lupus erythematosus. Autoimmunity 1991; 11: 61–66
   Web of Science ®Google Scholar
• Kerjashki D. The pathogenesis of membranous glomerulonephritis: from morphology to molecules. Virchows Arch B Cell Pathol 1990; 58: 253–71
   Google Scholar
• Salant D. J., Quigg RJ, Cybulsky A. V. Heymann nephritis: mechanisms of renal injury. Kidney Int 1989; 35: 976–84
   Google Scholar
• Deppisch R., Schmitt V., Bommer J., et al. Fluid-phase generation of terminal complement complex as a novel index of bioincompatibility. Kidney Int 1990; 37: 696–706
   PubMed Web of Science ®Google Scholar
• Mollnes T. E., Lea T., Mellbye O. J., et al. Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex. Arthritis Rheum 1986; 29: 715–21
   PubMedGoogle Scholar
• Kemp P. A., Spragg J. H., Brown J. C., et al. Immunohistochemical determination of complement activation in joint tissues of patients with rheumatoid arthritis and osteoarthritis using neoantigen-specific monoclonal antibodies. J Clin Lab Immunol 1992; 37: 147–62
   Google Scholar
• Engel A. G., Arahata K. The membrane attack complex of complement at the end plate in myasthenia gravis. Ann NY Acad Sci 1987; 505: 326–32
   PubMedGoogle Scholar
• Nakano S., Engel A. G. Myasthenia gravis: quantatative analysis of inflammatory cells and detection of complement membrane attack complex at the end plate in 30 patients. Neurology 1993; 43: 1167–72
   PubMed Web of Science ®Google Scholar
• Compston DAS, Morgan B. P., Campbell A. K., et al. Immunocytochemical localisation of the terminal complement complex in multiple sclerosis. Neuropathol Appl Neurobiol 1989; 15: 307–16
   PubMedGoogle Scholar
• Pabst H., Day N. K., Gewurz H., et al. Prevention of experimental allergic encephalomyelitis with cobra venom factor. Proc Soc Exp Biol Med 1971; 136: 555–60
   PubMed Web of Science ®Google Scholar
• Linington C., Morgan B. P., Scolding N. J., et al. The role of complement in the pathogenesis of experimental allergic encephalomyelitis. Brain 1989; 112: 895–911
   Google Scholar
• Grundke-Iqbal I., Bernstein M. B. Multiple sclerosis serum gamma globulins and demyelination in organ culture. Neurology 1980; 30: 749–54
   Google Scholar
• Sanders M. E., Koski C. L., Robbins D., et al. Activated terminal complement component in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis. J Immunol 1986; 135: 4456–9
   Google Scholar
• Sanders M. E., Alexander E. L., Koski C. L., et al. Detection of activated terminal complement (C5b-9) in cerebrospinal fluid from patients with central nervous system involvement of primary Sjogren's syndrome or Systemic Lupus Erythematosus. J Immunol 1987; 138: 2095–9
   PubMed Web of Science ®Google Scholar
• Koski C. L. Characterization of complement-fixing antibodies to peripheral nerve myelin in Guillain-Barre syndrome. Ann Neurol 1990; 27(Suppl)S44–S47
   Google Scholar
• Eikelenboom P., Hack C. E., Rozemuller J. M., et al. Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch (Cell Pathol) 1989; 56: 259–62
   Google Scholar
• Morgan B. P. Complement in diseases of the nervous system. Complement in health and disease, K. Whaley, M Loos, J. Weiler. Kluwer, Lancaster 1993; 353–75
   Google Scholar
• Jordon R. E., Kawana S, Fritz K. A. Inununopathologic mechanisms in pemphigus and bullous pemphigoid. J Invest Dermatol 1985; 85(Suppl)72S–78S
   Google Scholar
• Xia P., Jordon RE, Geoghegan W. D. Complement fixation by pemphigus antibody. J Clin Invest 1988; 82: 1939–47
   Google Scholar
• Boom B. W., Monunaas M., Daha M. R., et al. Complement-mediated endothelial cell damage in immune complex vasculitis of the skin: ultrastructural localization of the membrane attack complex. J Invest Dermatol 1989; 93(Suppl 2)68S–72S
   Google Scholar
• Tomita A., Parker C. J. Aberrant regulation of complement by the erythrocytes of hereditary erythroblastic multinuclearity with a positive acidified serum lysis test (HEMPAS). Blood 1994; 83: 250–9
   PubMed Web of Science ®Google Scholar
• Fukuda M. N., Gaetani G. F., Izzo P., et al. Incompletely processed N-glycans of serum glycoproteins in congenital dyserythropoietic anaemia Type II (HEMPAS). Br J Haematol 1992; 82: 745–52
   Google Scholar
• Kurata Y., Curd J. G., Tamerius J. D., et al. Platelet-associated complement in chronic ITP. Br J Haematol 1985; 60: 723–33
   Google Scholar
• Kirklin J. K., Westaby S., Blackstone E. H., et al. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Surg 1983; 86: 845–7
   Google Scholar
• Chenoweth D. E., Cooper S. W., Hugli T. E., et al. Complement activation during cardiopulmonary bypass. N Engl J Med 1981; 304: 497–503
   PubMed Web of Science ®Google Scholar
• Langlois P. F., Gawryl M. S., Zeller J., et al. Accentuated complement activation in patient plasma during the adult respiratory distress syndrome: a potential mechanism for pulmonary inflammation. Heart Lung 1989; 18: 71–84
   Google Scholar
• Hallgren R., Samuelsson T, Modig J. Complement activation and increased alveolar-capillary permeability after major surgery and in adult respiratory distress syndrome. Crit Care Med 1987; 15: 189–93
   Google Scholar
• Garred P., Olsen J., Mollnes T. E., et al. Biocompatibility of urinary catheters: effect on complement activation. Br J Urol 1989; 63: 367–71
   PubMedGoogle Scholar
• van der Linden PWG, Hack C. E., Kerckhaert JAM, et al. Preliminary report: complement activation in wasp sting anaphlaxis. Lancet 1990; 336: 904–6
   Google Scholar
• Yang Q-E, Wang Y. Y., Bollinger R. R., et al. Discordant complement systems as a factor in hyperacute rejection. Transplant Proc 1992; 26: 481–2
   Google Scholar
• Sinha D., Wells M, Faulk W. P. Immunological studies of human placentae: complement components in pre-eclamptic chorionic villae. Clin Exp Immunol 1984; 56: 175–80
   PubMedGoogle Scholar
• Tedesco F., Radillo O., Candussi G., et al. Immunohistochemical detection of terminal complement complex and S protein in normal and preeclamptic placentae. Clin Exp Immunol 1990; 80: 236–40
   PubMedGoogle Scholar
• Niculescu F., Rus HG, Vlaicu R. Immunohistochemical localization of C5b-9, S-protein, C3d and apolipoprotein B in human arterial tissues with atherosclerosis. Atherosclerosis 1987; 65: 1–11
   PubMedGoogle Scholar
• Seifert P. S., Kazatchkine M. D. The complement system in atherosclerosis. Atherosclerosis 1988; 73: 91–104
   Google Scholar
• Halstensen T. S., Mollnes TE, Brandtzaeg P. Persistent complement activation in submucosal blood vessels of active inflammatory bowel disease: immunohistochemical evidence. Gastroenterology 1989; 97: 10–19
   Google Scholar
• Weetman A. P., Cohen S. B., Oleesky D. A., et al. Terminal complement complexes and Cl/Cl inhibitor complexes in autoimmune thyroid disease. Clin Exp Immunol 1989; 77: 25–30
   PubMed Web of Science ®Google Scholar
• Price R. J., Boettcher B. The presence of complement in human cervical mucus and its possible relevance to infertility in women with complement-dependent sperm-immobilising antibodies. FertilSteril 1979; 32: 61–6
   PubMed Web of Science ®Google Scholar
• Link H. Complement factors in multiple sclerosis. Acta Neurol Scand 1972; 48: 521–8
   PubMed Web of Science ®Google Scholar
• Cyong J-C, Witkin S. S., Rieger B., et al. Antibody-independent complement activation by myelin via the classical complement pathway. J Exp Med 1982; 155: 587–98
   PubMed Web of Science ®Google Scholar
• Scolding N. J., Morgan B. P., Houston WAJ, et al. Normal rat serum cytotoxicity against syngeneic oligodendrocytes: complement activation and attack in the absence of anti-myelin antibodies. J Neurol Sci 1989; 89: 289–300
   PubMed Web of Science ®Google Scholar
• Scolding N. J., Morgan B. P., Houston WAJ, et al. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature (London) 1989; 339: 620–2
   PubMed Web of Science ®Google Scholar
• Piddlesden S. J., Morgan B. P. Killing of rat glial cells by complement: deficiency of the rat analogue of CD59 is the cause of oligodendrocyte susceptibility to lysis. J Neuroimmunol 1993; 48: 169–76
   Google Scholar
• Piddlesden S. J., Lasmann H, Laffafian I., et al. Antibody-mediated demyelination in experimental allergic encephalomyelitis is independent of complement membrane attack complex formation. Clin Exp Immunol 1990; 83: 245–50
   Google Scholar
• Piddlesden S. P., Storch M., Hibbs M., et al. Soluble complement receptor 1 (sCRl) inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J Immunol 1994; 152: 5477–84
   PubMed Web of Science ®Google Scholar
• Barnum S. R. Biosynthesis and regulation of complement by cells of the central nervous system. Complement Today 1993; 1: 76–95
   Google Scholar
• Mollnes T. E., Videm V., Risenfeld J., et al. Complement activation and bioincompatibility. Clin Exp Immunol 1991; 86(suppl)21–6
   Google Scholar
• Janatova J., Cheung A. K., Parker C. J. Biomedical polymers differ in their capacity to activate complement. Complement Inflammation 1991; 8: 61–9
   PubMedGoogle Scholar
• Forty J., Hasan R., Cary N., et al. Hyperacute rejection of rabbit hearts by human blood is mediated by the alternative pathway. Transplant Proc 1992; 26: 488–9
   Google Scholar
• White DJG. Transplantation of organs between species. Int Arch Allergy Immunol 1992; 98: 1–5
   Google Scholar
• Dalmasso A. P., Piatt JL, Bach F. H. Reaction of complement with endothelial cells in a model of xenotransplantation. Clin Exp Immunol 1991; 86(Suppl)31–5
   Google Scholar
• Leventhal J. R., Dalmasso A. P., Cromwell J. W., et al. Prolongation of cardiac xenograft rejection by depletion of complement. Transplantation 1993; 55: 857–66
   PubMed Web of Science ®Google Scholar
• Pruitt S. K., Baldwin W. M., Marsh H. C., et al. The effect of soluble complement receptor type 1 on hyperacute xenograft rejection. Transplantation 1991; 52: 868–73
   PubMed Web of Science ®Google Scholar
• Rooney I. A., Oglesby T. J., Atkinson J. P. Complement in human reproduction: activation and control. Immunol Res 1993; 12: 276–94
   PubMedGoogle Scholar
• D'Cruz O. J., Haas G. G., Wang B., et al. Activation of human complement by IgG antisperm antibody and the demonstration of C3 and C5b-9-mediated damage to human sperm. J Immunol 1991; 146: 611–20
   PubMed Web of Science ®Google Scholar
• O'Bryan M. K., Baker HWG, Saunders J. R., et al. Human seminal plasma clusterin (SP-40,40) isolation and characterisation. J Clin Invest 1990; 85: 1477–86
   PubMed Web of Science ®Google Scholar
• Rooney I A, Davies A, Morgan B. P. Membrane attack complex-mediated damage to spermatozoa: protection of the cells by the presence on their membranes of MAC inhibitory proteins. Immunology 1992; 75: 499–505
   Google Scholar
• Cervoni F., Oglesby T. J., Adams E. M., et al. Identification and characterisation of membrane cofactor protein of human spermatozoa. J Immunol 1992; 148: 1431–9
   PubMedGoogle Scholar
• Cervoni F., Oglesby T. J., Fenichel P., et al. Expression of decay accelerating factor (CD55) of the complement system on human spermatozoa. J Immunol 1993; 151: 939–48
   Google Scholar
• Taylor C. T., Biljan M. M., Kingsland C. R., et al. Inhibition of human sperm-oocyte interaction. in vitro by monoclonal antibodies to CD46 (membrane cofactor protein). Hum Reprod. 1994; 9: 907–11
   Google Scholar
• Rooney I. A., Atkinson J. P., Kml ES, et al. Physiologic relevance of the membrane attack complex inhibitory protein CD59 in human seminal plasma: CD59 is present on extracellular organelles (prostasomes), binds cell membranes and inhibits complement mediated lysis. J Exp Med 1993; 177: 1409–20
   PubMed Web of Science ®Google Scholar
• Holmes C. H., Simpson K. L., Okada H., et al. Complement regulatory proteins at the feto-maternal interface during human placental development. Eur J Immunol 1992; 22: 1579–85
   PubMed Web of Science ®Google Scholar
• Tedesco F., Narchi G., Radillo S., et al. Susceptibility of human trophoblast to killing by human complement and the role of complement regulatory proteins. J Immunol 1993; 151: 1562–70
   PubMed Web of Science ®Google Scholar
• Asghar S. S. Pharmacological manipulation of the complement system. Pharmacol Rev 1984; 36: 223–44
   PubMed Web of Science ®Google Scholar
• Edens R. E., Linhardt RJ, Weiler J. M. Heparin is not just an anticoagulant anymore: six and one half decades of studies on the ability of heparin to regulate complement activity. Complement Today, J. M. Cruse, RE Lewis, Jr. Karger., Basel 1993; 96–120
   Google Scholar
• Miyagawa S., Shirakura R., Matsuniiya G., et al. Effect of anticomplement reagents K-76COOH and FUT175 on discordant xenograft survival. Transplant Proc 1992; 24: 483–4
   Google Scholar
• Kalli K. R., Hsu P, Fearon D. T. Therapeutic uses of recombinant complement protein inhibitors. Springer Semin Immunopathol 1994; 15: 417–31
   PubMed Web of Science ®Google Scholar
• Weisman H. F., Bartow T., Leppo M. K., et al. Soluble complement receptor type 1: in vivo inhibitor of complement suppressing post-ischaemic myocardial inflammation and necrosis. Science 1990; 249: 146–51
   PubMed Web of Science ®Google Scholar
• Weisman H. F., Bartow T., Leppo M. K., et al. Recombinant soluble CR1 suppressed complement activation, inflammation and necrosis associated with reperfusion of ischaemic myocardium. Trans Assoc Am Physicians 1990; 103: 64–72
   PubMedGoogle Scholar
• Hill J., Lindsay T. F., Ortiz F., et al. Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischaemia – reperfusion in the rat. J Immunol 1992; 149: 1723–28
   PubMed Web of Science ®Google Scholar
• Pemberton M., Anderson G., Vetvicka V., et al. Microvascular effects of complement blockade with soluble recombinant CR1 on ischaemia/reperfusion injury of skeletal muscle. J. Immunol 1993; 150: 5104–13
   Google Scholar
• Mulligan M. S., Yeh G. C., Rudolph A. R., et al. Protective effects of soluble CR1 in complement and neutrophil mediated tissue injury. J Immunol 1992; 148: 1479–85
   PubMed Web of Science ®Google Scholar
• Homeister J. W., Satoh P. S., Kilgore K. S., et al. Soluble complement receptor type 1 prevents human complement-mediated damage of the rabbit isolated heart. J Immunol 1993; 150: 1055–64
   PubMed Web of Science ®Google Scholar
• Pruitt S. K., Kirk A. D., Bollinger R. R., et al. The effect of soluble complement receptor type I on hyperacute rejection of porcine xenografts. Transplantation 1994; 57: 363–70
   PubMed Web of Science ®Google Scholar
• Moran P., Beasley H., Gorrell A., et al. Human recombinant soluble decay accelerating factor inhibits complement activation. in vitro and. in vivo. J Immunol 1992; 149: 1736–43
   PubMed Web of Science ®Google Scholar
• Sugita Y., Ito K., Shiozuka K., et al. Recombinant soluble CD59 inhibits reactive haemolysis with complement. Immunology 1994; 82: 34–41
   PubMed Web of Science ®Google Scholar
• Piatt J. L., Vercellotti G. M., Dalmasso A. P., et al. Transplantation of discordant xenografts: a review of progress. Immunol Today 1990; 11: 450–6
   Google Scholar
• Marino I. R., Ferina G., Celi S., et al. Hyperacute rejection of renal discordant xenograft: model assessment and rejection mechanisms. Transplant Proc 1990; 22: 1071–6
   PubMedGoogle Scholar
• Johnstone P. S., Wang M-W, Lim SML, et al. Discordant xenograft rejection in an antibody-free model. Transplantation 1992; 54: 573–6
   Google Scholar
• Pruitt S. K., Kirk A. D., Bollinger R. R., et al. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994; 57: 363–70
   PubMed Web of Science ®Google Scholar